Archives
-
Cross-Kingdom Promoters: Promise and Limits
2026-10-12
A 2026 study reports modular hybrid promoters that produced weak, moderate, and strong expression in both Escherichia coli and Saccharomyces cerevisiae. The findings support a principled approach to portable gene regulation, but the evidence remains limited to two hosts and does not establish universal predictability across organisms or genetic contexts.
-
Oligo (dT) 25 Beads: Evidence and Scope
2026-10-12
APExBIO’s Oligo (dT) 25 Beads (SKU K1306) are supplier-described superparamagnetic beads bearing covalently attached oligo(dT) sequences. Their stated conceptual purpose is polyA tail mRNA capture for eukaryotic mRNA isolation. No matched research paper or independent performance dataset was identified in the supplied evidence, so claims about yield, purity, integrity, reproducibility, and downstream performance remain unverified here.
-
Stattic and STAT3 Signaling: Evidence Overview
2026-10-10
This overview evaluates Stattic as a research tool for studying STAT3 signaling, with emphasis on cancer biology and the STING–STAT3 axis in psoriasis. It separates supplier-reported compound claims from findings in a 2026 peer-reviewed study and outlines evidence strength, conceptual applications, and key limitations.
-
FK866 and the Translational Logic of NAMPT Biology
2026-10-09
FK866 (APO866) offers a focused way to study how NAMPT-dependent NAD metabolism connects cancer vulnerability, mitochondrial stress, and tissue resilience—while highlighting the limits of translating preclinical findings across disease contexts.
-
Ruxolitinib in Anaplastic Thyroid Cancer
2026-10-09
A source-grounded overview of what the 2024 anaplastic thyroid carcinoma study shows about Ruxolitinib phosphate, JAK1/2–STAT3 signaling, mitochondrial dynamics, cell death, evidence strength, and translational limits.
-
Sulfachloropyridazine: Five Evidence Questions
2026-10-08
A source-grounded overview of Sulfachloropyridazine, covering its proposed folate-pathway principle, evidence from chicken coccidiosis research, interpretation of microbiome and metabolomics findings, and the limits of applying those results across organisms or study types.
-
Cy5 Maleimide and the Physics of Condensates
2026-10-08
Cy5 maleimide is more than a fluorescent tag in condensate research: its conjugated charge, chemistry, and spectral behavior can shape interpretation. This article connects non-sulfonated Cy5 maleimide with new evidence on electrostatic partitioning in α-synuclein condensates.
-
Beyond Relative Viability in Cancer Drug Response
2026-10-07
Hannah Schwartz’s dissertation examines why relative viability alone can obscure the distinct contributions of growth inhibition and cell death in vitro. Its central contribution is a more discriminating framework for interpreting anticancer drug responses by considering response composition, magnitude, and timing rather than treating one viability value as a complete pharmacologic phenotype.
-
KG-501 in CREB–KIX and Cancer Research
2026-10-06
KG-501 is a small-molecule research tool associated with CREB–CBP KIX-domain disruption. In a 2024 study of colitis-associated colorectal cancer, it was included among pharmacological pathway antagonists used to examine how Jiedu Xiaozheng Yin affected macrophage polarization. The findings support a TLR4-linked immune-modulation hypothesis, but they do not establish KG-501 as the active cause of the reported antitumor effects or as a treatment for colorectal cancer.
-
Prochlorperazine-Induced Neuroleptic Malignant Syndrome
2026-10-06
This case report describes neuroleptic malignant syndrome (NMS) in a 76-year-old man after prochlorperazine exposure, despite only modest creatine phosphokinase elevation and otherwise unremarkable laboratory findings. Its main contribution is diagnostic: clinical pattern recognition, medication history, and exclusion of competing emergencies may remain decisive when classic laboratory abnormalities are absent.
-
Pazopanib Hydrochloride: Evidence and Research Context
2026-10-05
Pazopanib Hydrochloride, also known as GW786034, is a multi-target receptor tyrosine kinase inhibitor studied in renal cell carcinoma and soft tissue sarcoma. This overview compares clinical evidence with in vitro response metrics, emphasizing what published findings support, where interpretation remains uncertain, and why growth inhibition should not be equated automatically with cell death.
-
Gap19: Cx43 Hemichannel Research Context
2026-10-05
Gap19 is studied as a selective connexin 43 hemichannel blocker, with reported effects on macrophage inflammatory signaling, astrocyte ATP release, and experimental cerebral ischemia. The strongest supplied evidence concerns AngII-treated RAW264.7 macrophages; neuroprotection and JAK2/STAT3 claims remain more dependent on commercial summaries and require primary-source verification.
-
Ruxolitinib in ATC: Apoptosis and Pyroptosis
2026-10-04
A 2024 Cell Death and Disease study links ruxolitinib activity in anaplastic thyroid carcinoma to suppression of STAT3-dependent DRP1 transcription, impaired mitochondrial fission, and activation of apoptosis and GSDME-mediated pyroptosis. The findings identify a mechanistic connection between JAK1/2-STAT3 signaling and mitochondrial dynamics, while remaining limited to preclinical evidence.
-
Lopinavir (ABT-378): Evidence Beyond HIV
2026-10-03
Lopinavir is best established as an HIV protease inhibitor, while evidence for activity against MERS-CoV comes primarily from a 2014 cell-culture screening study. This overview compares those evidence streams, explains what the reported low-micromolar EC50 values do and do not show, and outlines the limits on interpreting lopinavir as a broadly useful coronavirus antiviral.
-
FDA-Approved Screening Reveals MERS-CoV Inhibitors
2026-10-02
de Wilde and colleagues screened an FDA-approved compound library and identified four small molecules, including Lopinavir, that inhibited MERS-CoV replication in cell culture at low-micromolar concentrations. The study demonstrates the value of phenotypic drug repurposing for emerging coronavirus threats while emphasizing that cell-based activity requires further mechanistic, pharmacological, and in vivo validation.